Alpha Teknova, Inc.

NasdaqGM TKNO

Alpha Teknova, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -88.14%

Alpha Teknova, Inc. EBT Margin is -88.14% for the Trailing 12 Months (TTM) ending September 30, 2024, a 19.53% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Alpha Teknova, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -109.53%, a -19.07% change year over year.
Alpha Teknova, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -91.99%, a -386.48% change year over year.
Alpha Teknova, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -18.91%.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqGM: TKNO

Alpha Teknova, Inc.

CEO	Mr. Stephen Gunstream
IPO Date	June 25, 2021
Location	United States
Headquarters	2290 Bert Drive
Employees	210
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.

Key trends

Past 5 years